Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.
about
Mechanistic differences in RNA-dependent DNA polymerization and fidelity between murine leukemia virus and HIV-1 reverse transcriptasesA new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidineAntiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv miceIn vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracilCross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virusA novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individualsHIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infectionVirulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.HIV-1 drug resistance: can we overcome?Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitorsPre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovirRole of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients.Retrovirus reverse transcriptases containing a modified YXDD motif.Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.Significant reductions in Gag-protease-mediated HIV-1 replication capacity during the course of the epidemic in JapanThe Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation.Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response.Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus.Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study.
P2860
Q28302073-DDD74FA9-F8B9-4060-BA8E-09958D835142Q28343476-5ADA7B5E-7054-4521-AB51-F4BCE364EB6DQ28343930-B9134CE5-A408-49D8-8103-2BF2C68F870EQ28345952-E8A137A3-7641-4D11-BC6B-F8F55952DB23Q28365198-3A0EFDFF-CC15-4EF4-B9EA-99FA7A717F92Q33724247-5BFE1911-B222-4AAC-AAD4-1A57269A0154Q33906239-314ED5AC-6D3C-4615-931D-6BD1AFA83277Q33983070-FF7B184F-FDC3-43F5-B1BF-E2FE6AACE852Q34052838-886FC955-1330-473E-A8D0-44BDC090A168Q34249966-7D7DD918-914E-43F5-8E38-65127A7144FFQ34330667-26A6E090-3EF1-4A1F-ACE0-76420A99B08AQ34339657-F75DFEA3-88D2-4658-9FEE-016155A6AC83Q34465037-71234F2F-1C27-43E5-927E-E5A4AE1745F9Q34974754-452871DC-8092-4158-8FF3-805C033E2134Q35043368-428DFCCA-1563-4734-AF0A-F9CB5EFBFA25Q35558801-FC69CC6D-3E30-4B3F-935C-866114B1ECD1Q35566910-D5071106-5CD8-4BC6-BE60-F683E29B7550Q35635667-69BBC32F-759F-4698-B21B-E5FF6DABE6E6Q35636514-0E5A38BF-78CE-41C3-9C61-92D9FCC2125EQ35842525-FE3A6964-5B77-4F74-9B5A-1CE974843F5EQ35912746-802CF079-85AD-418D-8028-36F11CD9815BQ35921994-31CECFE5-C9DA-4FA7-9F48-F74471AE2C2EQ36186797-07D66442-8995-4DE8-864B-AB006EEC7A80Q36246775-70E56091-6D8A-4986-B785-C8622C9B8F96Q36559805-41285F7A-864D-45F2-992B-1086392D2649Q37018369-943BEC50-3ECA-45DE-A848-76732EF4EF0EQ38344427-8218F104-65F3-44FE-8968-0316774D3001Q39652300-A3BCCB66-9044-4BCD-9948-4112792B38F0Q39657878-B96AEFC0-ABF5-4A2C-92C7-697F043D051EQ39740543-61FF0FF4-EF31-43E9-A3FC-20F390E76149Q40173457-37DABC31-49FF-40F0-B4CF-51FA1D055546Q40404514-D8DC1C1D-1167-4C3A-BC60-995B6324D693Q40706086-4438B4EF-6B38-42CD-BA34-D7C1DBCA814DQ40902737-24196870-AFE2-46D5-823C-76B34A9C2B91Q41820283-6CCFF331-0263-4C64-A322-15F6F53F8EF4Q43741648-BE1B6848-8D49-4B69-A780-F40EE105FF4CQ43993272-47B894AD-B6E4-4BA6-B74B-498AD63A94C0Q44584141-1ECDEAF8-5223-483D-B234-572D1C08DDBCQ46450181-A34C9AE4-68E6-4FC0-830D-6EFD995A3E36Q51481656-8DC02A9D-B416-4EC7-8A20-723B992BA0E3
P2860
Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Human immunodeficiency virus t ...... plication capability in vitro.
@en
Human immunodeficiency virus t ...... plication capability in vitro.
@nl
type
label
Human immunodeficiency virus t ...... plication capability in vitro.
@en
Human immunodeficiency virus t ...... plication capability in vitro.
@nl
prefLabel
Human immunodeficiency virus t ...... plication capability in vitro.
@en
Human immunodeficiency virus t ...... plication capability in vitro.
@nl
P2093
P356
P1476
Human immunodeficiency virus t ...... plication capability in vitro.
@en
P2093
A S Mulato
J M Cherrington
M D Miller
P304
P356
10.1086/314560
P407
P577
1999-01-01T00:00:00Z